Ligand Pharmaceuticals Incorporated

LGND Healthcare Biotechnology

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue
−31.8%
EPS
−123.9%
Free cash flow
−268.5%
Total debt
+52.6%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%
Market cap
$6.0B
P/E
116×
Fwd P/E
88.3×
Dividend yield
—
F-score
6/9
Altman Z
5.45
Beneish M
−4.02
Dividend safety
n/a

Ligand Pharmaceuticals Incorporated (LGND) EV/FCF

Alert me on EV/FCF

As of 5 November 2026, Ligand Pharmaceuticals Incorporated (LGND) trades at a EV/FCF of 60.7×. Over the past ten years it has ranged from −491× (July 2024) to 154× (October 2019); the current reading is higher than 91% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 56.2× 183.84%
FY2024 19.8× —
FY2023 −302× —
FY2022 8.8× (66.16%)
FY2021 26.1× 8.21%
FY2020 24.1× —
FY2019 −27.7× —
FY2018 10.0× (55.16%)
FY2017 22.2× (43.23%)
FY2016 39.2× 3.90%

Quarterly newest first

Period EV/FCF Change
Sep 2026 63.0× 46.29%
Jun 2026 43.1× 56.58%
Mar 2026 27.5× (51.05%)
Dec 2025 56.2× (55.51%)
43 more quarters

Against its own ten years

Low −491× High 154×
Ten-year median 33.6×
Current reading's percentile 89

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on LGND